Theranostic prostate cancer trial advances to cohort 2
Filed with ASX · · 4 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity Receives $6.7 million R&D Tax Incentive Refund
- Clarity Corporate Presentation
- 50% recruitment milestone for NET diagnostic Phase II trial
- PROPELLER Trial Results
- Diagnostic prostate cancer trial reaches recruitment target
Later from Clarity Pharmaceuticals
- Recruitment complete for Phase II prostate cancer trial
- Presentation at Jefferies Healthcare Conference
- Clarity expands supply of Cu-64 for Phase III trials
- COMBAT theranostic prostate cancer trial commences in the US
- Northstar Achieves Key Production Milestones
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals